A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

This phase I/II neoadjuvant trial (ClinicalTrials.gov identifier NCT00066443) determined maximally-tolerated doses (MTD), dose-limiting toxicities, response-to-therapy, and explored the role of novel response biomarkers. MA.22 accrued T3N0, any N2 or N3, and T4 breast cancer patients. Treatment was...

Descripción completa

Detalles Bibliográficos
Autores principales: Trudeau, Maureen Elizabeth, Chapman, Judith-Anne W., Guo, Baoqing, Clemons, Mark J., Dent, Rebecca A., Jong, Roberta A., Kahn, Harriette J., Pritchard, Kathleen I., Han, Lei, O’Brien, Patti, Shepherd, Lois E., Parissenti, Amadeo M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627986/
https://www.ncbi.nlm.nih.gov/pubmed/26543765
http://dx.doi.org/10.1186/s40064-015-1392-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627986/
https://www.ncbi.nlm.nih.gov/pubmed/26543765
http://dx.doi.org/10.1186/s40064-015-1392-x

Ejemplares similares